Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma × Decision Support Techniques × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 9 Colorectal Neoplasms 6 Prostatic Neoplasms 3 Neoplasms 3 Ovarian Neoplasms 2 Colonic Neoplasms 2 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Patient Participation 1 Neuroma, Acoustic 1 Melanoma 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Kidney Neoplasms 1 Healthy Volunteers 1 Depression 1 Dementia 1 Colorectal Cancer Screening 1 Carcinoma, Renal Cell 1 COVID-19 1 Breast Carcinoma In Situ 1 Behavior 1 Advanced Cancer 1

Interventions

pembrolizumab 242 Nivolumab 219 Ipilimumab 197 aldesleukin 116 Cyclophosphamide 116 Interleukin-2 87 trametinib 64 Dacarbazine 62 fludarabine 59 Vemurafenib 59 Temozolomide 59 dabrafenib 57 fludarabine phosphate 52 Radiosurgery 41 sargramostim 39 Biopsy 38 Bevacizumab 38 incomplete Freund's adjuvant 35 binimetinib 33 Paclitaxel 32 Cisplatin 31 Radiotherapy 30 Magnetic Resonance Spectroscopy 30 cobimetinib 28 atezolizumab 28 encorafenib 27 Specimen Handling 27 Introns 27 Carboplatin 27 CTLA-4 Antigen 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04240717 2022-11-07

PEF-Immun

University Hospital Heidelberg

Phase NA Completed

Melanoma, Patient Participation

Data powered by HemOnc (CC BY 4.0) Colophon ⚡